Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway

Endometrial cancer (EC) is the most common gynecologic malignancy in the developed countries [1]. Statistical analysis has shown that approximately 142000 women suffered from EC globally every year, and approximately 42000 women die from this disease [2]. Amongst these EC cases, approximately 80% are endometrioid EC (EEC) [3], which is mainly treated with combination of surgery and adjuvant chemotherapy, radiotherapy or hormone therapy. However, these conventional chemotherapy and radiotherapy cause side effects for advanced patients or yield suboptimal results for those with recurrent EEC [4]. Therefore, it is a strong medical need to develop a novel therapeutic agent against EEC that exhibit reduced toxicity and increased efficiency.

Shikonin, an active naphthoquinone of Zi Cao, derived from the roots of the herb Lithospermu erythrorhizon that has been used in traditional Chinese medicine to treat skin diseases, burns and sore throats due to its antimicrobial and anti-inflammatory activities [5,6]. Recently, it has been identified that shikonin exerts various anticancer effects such as inhibiting proliferation and promoting apoptosis in human lung adenocarcinoma cells, suppressing prostate cancer cell metastasis, weakening migration and invasion in human breast cancer cells [7–10]. Liu et al. [11] uncovered that shikonin protects against concanavalin A-induced acute liver injury via inhibition of the JNK pathway in mice. Jang et al. [8] demonstrated that shikonin attenuates human breast cancer cells migration and invasion via suppressing matrix metalloproteinase-9 activation. Wang et al. [12] clarified that shikonin inhibits interleukin-1β-induced chondrocytes’ apoptosis through modulating PI3K/AKT signaling pathway. Furthermore, it has been reported that shikonin possesses the suppressive effects on EEC cells via promoting apoptosis and blocking cell cycle [13]. However, the molecular mechanism of the anticancer effects of shikonin on EEC cells remain unclear.

miRNAs are a group of endogenous, non-coding small RNAs of 22–25 nts, which serve as a regulator of gene expression at the post-transcriptional level via suppressing translation or promoting RNA degradation. There is a growing body of evidence that miRNAs are involved in a variety of biological and pathological processes including cellular differentiation, proliferation, apoptosis, and carcinogenesis [14–16]. In recent years, it has been extensively reported that some Chinese medicinal herbs exert antitumor effects in different cancers via regulating miRNA expression profiles [17,18]. Curcumin suppresses cell growth, invasion, tumor growth in colorectal cancer and in vivo metastasis by regulation of miR-21 [19]. Zhang et al. [20] illustrated that honokiol inhibits bladder tumor growth by blocking the EZH2/miR-143 axis. In addition, shikonin has been identified to act as a potential therapeutic agent to treat human glioblastoma through regulating miRNA expression profiles [21]. Against this background, we hypothesized that shikonin exerts anticancer effect on human EEC via modulating miRNA expression.

In the present study, we investigated the anticancer effects of shikonin on EEC cells and explored the underlying molecular mechanism by identifying shikonin-induced miRNA dysregulations. Our results suggested that shikonin may possess anticancer effects on EEC via mediating miR-106b/phosphatase and tensin homolog (PTEN)/AKT/mTOR signaling pathway and act as a potential therapeutic agent for the treatment of EEC.

Twenty EEC tissues and twenty normal endometrial samples were collected from patients who underwent surgical resection at Gynecology of Traditional Chinese Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai TCM University (Shanghai, China) between April 2016 and April 2017. None of the patients had received pre-operative radiotherapy or chemotherapy prior to surgical resection. The tumor specimens were independently confirmed by two pathologists. Fresh specimens were snap-frozen in liquid nitrogen and stored at −80°C immediately after resection for subsequent RNA extraction. The project protocol was approved by the Ethics Committee of Shanghai TCM University. All patients provided written informed consents for the use of the tumor tissues for clinical research.

The human EEC cell lines Ishikawa, HEC-1A, KLE, and RL95-2 were obtained from American Type Culture Collection (ATCC, Manassas, VA, U.S.A.) and one normal endometrial cell (ESC) were obtained from the Tumor Cell Bank of the Chinese Academy of Medical Science (Peking, China), and maintained in DMEM, supplemented with streptomycin (100 IU/ml), penicillin (100 IU/ml, Sigma, St. Louis, MO), 2 mM glutamine, and 10% FBS (Gibco BRL, Grand Island, NY). Cells (1 × 10⁴/well) were seeded in 96-well plates for 24 h and then incubated with shikonin (10–20 μM) at 24 h for further measurements. Shikonin was purchased from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China) with purity >99%. Shikonin was dissolved in DMSO (Sigma) and stored at −20°C.

The Cell Counting Kit-8 (CCK-8) assay was used to measure proliferation of cells according to the manufacturer’s instruction (Beyotime Institute of Biotechnology, Shanghai, China). The cells (5 × 10⁴ cells/well) were seeded in 96-well plate with 100 μl DMEM medium supplemented with 10% FBS. After 48 h incubation, 10 μl CCK-8 reagent dissolved with 100 µl DMEM was added to each well and continuously cultured for 1 h in 5% CO₂ (Thermo). The absorbance rate at 450 nm were measured by Microplate Reader (Bio–Rad, U.S.A.). All experiments were performed in quintuplicate on three separate occasions.

The flow cytometry analysis was used to measure cell apoptosis. The cells were treated with shikonin for 24 h, and were then collected and washed twice with PBS. After treatment with trypsin, cells were fixed with 70% ice-cold methanol at 4°C for 30 min. Cells were resuspended in binding buffer and stained with 5 μl of AnnexinV-FITC (BD, Mountain View, CA, U.S.A.) and 1 μl of propidium iodide (PI, 50 μg/ml) (BD, Mountain View, CA, U.S.A.). Flow cytometric evaluation was performed within 5 min. Stained cells were analyzed using flow cytometry (BD, FACSCalibur, CA, U.S.A.). The measurements were performed independently for at least three times with similar results.

miRNA microarray analysis was used to evaluate miRNA expression in cells after treatment with shikonin. Total RNA was isolated from cells using TRIzol reagent (Molecular Research Center, Inc., Cincinnati, OH, U.S.A.) and purified by RNeasy MinEluted Cleanup kit (QIAGEN, Germany) according to manufacturer’s instructions. After measuring the quantity of RNA using a NanoDrop 1000 (Youpu Scientific Instrument Co., Ltd., Shanghai, China), the samples were labeled using the miRCURY™Hy3™/Hy5™ Power labeling kit (Exiqon, Vedbaek, Denmark) and hybridized on a miRCURY™ LNA Array (version 18.0, Exiqon, Vedbaek, Denmark). After washing, the slides were scanned using an Axon GenePix 4000B microarray scanner (Axon Instruments, Foster City, CA, U.S.A.). Scanned images were then imported into the GenePix Pro6.0 program (Axon Instruments) for grid alignment and data extraction. Replicated miRNAs were averaged, and miRNAs with intensities ≥50 in all samples were used to calculate a normalization factor. Expressed data were normalized by median normalization. After normalization, the miRNAs that were significantly differentially expressed were identified by Volcano Plot filtering. Hierarchical clustering was used to determine the differences in the miRNA expression profiles amongst different genes and samples using MEV software (version 4.6; TIGR, Microarray Software Suite4, Boston, U.S.A.).

Total RNA was extracted from culture cells using TRIzol Reagent (Invitrogen) and quantitated with UV spectrophotometer (SmartSpec plus). The High Capacity cDNA Synthesis Kit (Applied Biosystems) was used to synthesize cDNA with miRNA-specific primers. The primers for miR-106b and the internal control RNU44 gene were obtained from Ambion. The real-time quantitative PCR (RT-qPCR) was carried out using TaqMan Gene Expression Assay (Applied Biosystems) on an Applied Biosystems 7500 Real-Time PCR machine. The 2^−ΔΔC_t method was used to determine the miRNAs relative expression. All reactions were performed in triplicate.

The cells were lysed as described previously [22]. The protein concentration was measured using BCA protein assay kit (Pierce, Rockford, IL). Total proteins (60 μg) were separated in SDS/polyacrylamide gels (10% gels) (Sigma–Aldrich, St. Louis, MO) and then transferred on to PVDF membranes (BD Pharmingen, San Diego, CA). After blocking with 5% non-fat milk at room temperature for 1 h, the PVDF membranes were incubated primary antibodies against cleaved-Caspase-3, Bax, Bcl-2, PTEN, p-AKT, AKT, p-mTOR, and mTOR at 4°C overnight. These antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). β-actin (Sigma, St. Louis, MO, U.S.A.) was used as an internal control. Horseradish peroxidase-conjugated (HRP) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used as the secondary antibodies. Subsequently, the protein bands were scanned on the X-ray film using the ECL detection system (PerkinElmer Life and Analytical Sciences, Boston, MA). The alpha Imager software (Alpha Innotech Corporation, San Leandro, CA) was used to measure relative intensity of each band on Western blots. The measurements were performed independently for at least three times with similar results.

The potential binding site between PTEN and miR-106b was identified using TargetScan (http://www.targetscan.org). The miR-106b mimics/inhibitor and corresponding negative control (NC) were synthesized by RiboBio (Guangzhou, China). The wild-type (wt) PTEN-3′-UTR and mutant (mut) PTEN-3′-UTR containing the putative binding site of miR-106b were established (Figure 5A) and cloned in the firefly luciferase expressing vector pMIR-REPORT (Ambion, U.S.A.). Site-directed mutagenesis of the PTEN 3′-UTR at the putative miR-106b binding site was performed by a QuikChange Kit (Qiagen). For the luciferase assay, Ishikawa cells at a density of 2 × 10⁵ per well were seeded into 24-well plates and co-transfected with 0.8 μg of pMIR-PTEN-3′-UTR or pMIR-PTEN-mut-3′-UTR, 50 nM miR-106b mimic/inhibitor or corresponding mimic NC using Lipofectamine 2000 reagent (Invitrogen). The relative firefly luciferase activity normalized with Renilla luciferase was measured 48 h after transfection by using the Dual-Light luminescent reporter gene assay (Applied Biosystems).

All statistical analyses were performed using SPSS 14.0 software (Chicago, IL). Each experiment was repeated at least three times. Numerical data are presented as the mean ± S.E.M. The comparison between data was calculated using Student’s ttest (between two groups) and one-way ANOVA and Tukey’s multiple comparison tests (between multiple groups). P-value of <0.05 was considered significant and <0.01 was considered very significant.

To explore the antiproliferative effect of shikonin on EEC cells, the human EEC cell lines Ishikawa, HEC-1A, KLE, and RL95-2 were treated with various concentrations of shikonin (0, 1, 2, 4, 8, 10, and 20 μM) for 24 h and the cell viability was evaluated by CCK-8 assay. As shown in Figure 1A–D, shikonin markedly reduced cell viability in a dose-dependent manner compared with blank group in all human EEC cell lines (P<0.01). The shikonin IC₅₀ values (the concentration of 50% inhibition cell viability) were 3.63, 4.81, 8.22, and 8.96 μM in Ishikawa, HEC-1A, KLE, and RL95-2, respectively. The most sensitive EEC cell lines Ishikawa and HEC-1A for shikonin were selected in the subsequent experiments. To determine the induction of cell apoptosis by shikonin in the human EEC cell lines, the Ishikawa and HEC-1A cells treated with 5 μM of shikonin for 24 h, and the apoptotic cells were evaluated using flow cytometric analysis. Compared with blank group, shikonin treatment significantly increased apoptotic cells in both Ishikawa and HEC-1A cells (P<0.01; Figure 1E). To further explore the molecular mechanisms of shikonin-induced apoptosis, we performed the Western blot analysis to measure the expression levels of the apoptosis-related proteins in Ishikawa and HEC-1A cells treated with 5 μM of shikonin for 24 h. We found that shikonin markedly up-regulated the pro-apoptotic proteins (cleaved-Caspase-3 and Bax) and down-regulated the anti-apoptotic protein (Bcl-2) compared with blank group (P<0.01; Figure 1F,G). Collectively, we first demonstrated that shikonin inhibits proliferation and induces apoptosis in human EEC cells.

Recently, many Chinese medicinal herbs were demonstrated to harbor the antitumor effects in various cancers through modulating miRNA expression profiles [17,18]. To investigate whether shikonin suppresses EEC cells’ growth via regulating miRNAs expression, we performed microarray analysis to determine miRNA levels in EEC cells after treatment with shikonin (5 μM) for 24 h. As shown in Figure 2A, compared with blank group, shikonin treatment resulted in aberrant expression of miRNAs, and miR-106b is one of the miRNAs being most significantly down-regulated in EEC cells. It is well reported that miR-106b has been identified to act as an oncogene in various cancers including breast cancer, osteosarcoma, and hepatocellular carcinoma [23–25]. To explore the role of miR-106b in the suppressive effects of shikonin on EEC cells, the Ishikawa cells were treated with various concentration of shikonin (0, 1, 2, 5, and 10 μM) for 24 h and miR-106b levels were quantitated by qRT-PCR. We observed that shikonin reduced the miR-106b expression in a dose-dependent manner in Ishikawa cells (Figure 2B). These data suggested that shikonin may exert anticancer effects via suppressing the expression of oncogenic miR-106b in EEC cells.

miR-106b has been demonstrated to function as an oncogene in many cancers [23–25], but its role in EEC has yet to be elucidated. To investigate the role of miR-106b in EEC, we performed the qRT-PCR to determine miR-106b expression in EEC tissues and found that miR-106b is dramatically up-regulated in cancer tissues compared with normal tissues (P<0.01; Figure 2C). Moreover, our results further verified that miR-106b is also significantly overexpressed in EEC cell lines (Ishikawa, HEC-1A, KLE, and RL95-2) compared with ESC cell (P<0.01; Figure 2D). These results indicated that miR-106b may play an oncogenic role in the development of EEC. To further explore the effects of miR-106b on EEC cells, the Ishikawa and HEC-1A cells were transfected with miR-106b inhibitor or inhibitor NC, and then cell viability and apoptotic cells were measured by CCK-8 assay and cytometric analysis, respectively. As shown in Figure 3A–C, compared with inhibitor NC, knockdown of miR-106b markedly reduces cell viability and increases apoptotic cells (P<0.01). In addition, our results demonstrated that knockdown of miR-106b up-regulated the pro-apoptotic proteins (cleaved-Caspase-3 and Bax) and down-regulated the anti-apoptotic protein (Bcl-2) compared with inhibitor NC group (Figure 3D,E). Taken together, these findings suggested that miR-106b is overexpressed in EEC tissues and cells, and function as an oncogene in EEC.

Based on the above results, our data demonstrated that miR-106b was down-regulated in Ishikawa cells after treatment with shikonin. Moreover, miR-106b was identified to act as an oncogene in EEC. Therefore, we speculated whether shikonin possesses the antiproliferation effects on EEC cells through modulating miR-106b expression. Then, the Ishikawa or HEC-1A cells were transfected with miR-106b mimics or mimics NC, and treated with shikonin (5 μM) for 24, 48, and 72 h. Subsequently, the cellular proliferation and apoptotic cells were measured by CCK-8 assay and cytometric analysis, respectively. We found that shikonin treatment dramatically inhibits cell proliferation and promotes apoptosis in shikonin + mimic NC group compared with blank group, but these suppressive effects of shikonin on EEC cells were abolished by overexpression of miR-106b in shikonin + miR-106b mimic group (P<0.01; Figure 4A–D). These results indicated that the shikonin may exert suppressive effects on EEC cells via regulating miR-106b expression. However, the precise molecular mechanisms by which shikonin represses EEC cell growth needs further research.

Previous studies uncovered that miR-106b could post-transcriptionally inhibit PTEN expression in different cancer cells, such as pituitary adenoma, breast cancer, and colorectal cancer [23,26–28], but whether PTEN was a direct target of miR-106b in human EEC cells remains to be further elucidated. Moreover, we further predicted the target genes of miR-106b using TargetScan, and identified PTEN as a potential target of miR-106b (Figure 5A). Subsequently, we constructed luciferase-reporter plasmids that contain the wt or mut 3′-UTR segments of PTEN (Figure 5A). The wt or mut reporter plasmid was co-transfected into Ishikawa cells along with miR-106b mimics/inhibitor or NC, and measured the luciferase activity. We observed that miR-106b mimic dramatically suppressed the luciferase activity compared with the mimic NC, but miR-106b inhibitor significantly increased the luciferase activity compared with the inhibitor NC (P<0.01; Figure 5D). Additionally, miR-106b did not inhibit the luciferase activity of the reporter vector containing 3′-UTR of PTEN with mutations in the miR-106b-binding site (Figure 5D). To further validate that the PTEN level is regulated by miR-106b, the Ishikawa or HEC-1A cells were transfected with miR-106b mimic/inhibitor or NC and Western blot was used to detect PTEN level. As shown in Figure 5B,C, up-regulation of miR-106b reduced the PTEN protein level compared with NC, conversely, knockdown of miR-106b increased the PTEN protein expression. These data indicated that miR-106b suppresses PTEN expression by directly targetting its 3′-UTR in human EEC cells.

To investigate the role of PTEN in human EEC cells, the Ishikawa or HEC-1A cells were transfected with pc-DNA-PTEN or pc-DNA-vector and then cell viability and apoptosis were measured by CCK-8 assay and flow cytometric analysis, respectively. As shown in Figure 6A, the PTEN protein expression was obviously u-pregulated in both Ishikawa and HEC-1A cells transfected with pc-DNA-PTEN compared with pc-DNA-vector (P<0.01). Moreover, our results showed that overexpression of PTEN significantly suppressed proliferation and promotes apoptosis in both Ishikawa and HEC-1A cells compared with pc-DNA-vector (P<0.01; Figure 6B,C). These results indicated that PTEN may act as a tumor suppressor gene in human EEC cells.

AKT/mTOR signaling which is negatively modulated by PTEN is a key pathway in cell survival, cellular proliferation, and tumor growth [29–31]. Recent studies demonstrated that miR-106b promotes the cell proliferation, invasion, and migration in a variety of cancers via modulating PTEN/PI3K/AKT signaling pathway [23,26,27]. Inspired by these studies, we hypothesized whether shikonin-induced miR-106b down-regulation modulates PTEN/AKT/mTOR signaling pathway in EEC cells. To verify this hypothesis, after transfection with or without miR-106b mimics, the Ishikawa or HEC-1A cells were treated with shikonin (5 μM) for 24 h and PTEN, AKT and mTOR were identified using Western blot. Our results showed that shikonin treatment markedly increased PTEN expression and decreased the p-AKT and p-mTOR levels compared with blank group in both Ishikawa and HEC-1A cells, but this shikonin-blocked PTEN/AKT/mTOR pathway was reactivated by overexpression of miR-106b (P<0.01; Figure 7A–D). These data illustrated that shikonin is able to repress the PTEN/AKT/mTOR signaling pathway in human EEC cells, but it could be reactivated by miR-106b overexpression. Taken together, these results suggested that shikonin blocks PTEN/AKT/mTOR signaling pathway via suppressing miR-106b expression in human EEC cells.

Emerging evidence revealed that shikonin exerts the anticancer effect in various cancers [7–11]. However, whether shikonin exhibits such anticancer functions when used in the context of the treatment of human EEC remains unclear. In the present study, we investigated the suppressive effects of shikonin on EEC cells, and explored the underlying molecular mechanisms. We observed that shikonin suppresses proliferation of EEC cells in a dose-dependent manner, and induced apoptosis via regulation of apoptosis-related proteins. Microarray analyses uncovered that shikonin induces a large set of miRNAs dysregulation, and the miR-106b was one of the miRNAs being most significantly down-regulated. Moreover, we confirmed that miR-106b is up-regulated in EEC tissues and cells, and the suppressive effects of shikonin were abrogated by overexpression of miR-106b in EEC cells. More importantly, our results indicated that shikonin represses proliferation and induces apoptosis in ECC cells via modulating miR-106b/PTEN/AKT/mTOR axis.

The naturally derived products with anticancer effects have been widely utilized as the source of many medically beneficial drugs, such as curcumin, camptothecin, luteolin, honokiol, isoflavone, matrine, xanthoangelol, and shikonin [7,32,33]. Xanthoangelol, isolated from Angelica keiskei roots, which suppressed tumor growth, metastasis to the liver and lung, and tumor-associated macrophage expression in tumors [33]. Icaritin, a traditional Chinese herbal medicine, which induces sustained ERK1/2 activation, represses human EC cells growth and promotes apoptosis [34]. With regard to shikonin, it has been identified to act as a potential anticancer agent against various cancers, including human lung adenocarcinoma, prostate cancer, and breast cancer [7–10]. However, the anticancer effects of shikonin on EEC were rarely reported. In the present study, our results showed that shikonin inhibits EEC cell growth in a dose-dependent manner, and induces apoptosis in EEC cells via activating the intracellular apoptotic signaling pathway. These data indicated that shikonin exerts the antiproliferative property in EEC cells and could be developed as a potential therapeutic agent against human EEC.

Growing evidence demonstrated that many miRNAs play key role in a variety of cancers, while the anticancer effects of traditional Chinese herbal medicine that operate through targetting miRNAs have also been widely reported. Zeng et al. [35] revealed that camptothecin induces human cervical cancer cells’ and human prostate cancer cells’ apoptosis via miR-125b-mediated mitochondrial pathways. Liu et al. confirmed that berberine could target the miR-21/PDCD4 axis, and improves cisplatin sensitivity in ovarian cancer cells [17]. In addition, shikonin has been demonstrated to act as a therapeutic agent to treat human glioblastoma via regulating miRNAs expression profiles [21]. In the present study, we performed microarray analysis to identify miRNAs expression in EEC cells treated with shikonin, and found that shikonin alters a large set of miRNAs and miR-106b was one of the miRNAs being most significantly down-regulated. Previous studies have demonstrated that miR-106b function as an oncogene in different cancers, such as breast cancer, osteosarcoma, and hepatocellular carcinoma [23–25]. Therefore, the miR-106b attracts us to investigate its role in EEC cells. Our results first demonstrated that miR-106b functions as an oncogene in EEC, and knockdown of miR-106b suppresses cell proliferation and apoptosis via modulating the intracellular apoptotic signaling pathway. Against this background, we hypothesized that shikonin may exert the anticancer effect in EEC through suppressing this oncogenic miRNA. Our results confirmed that the antiproliferative and pro-apoptotic effects of shikonin on EEC cell were abolished by miR-106b overexpression. These data suggested that shikonin may exert the suppressive effects on EEC cells via down-regulating miR-106b. However, the precise molecular mechanism needs further research to be understood deeply.

AKT/mTOR signaling plays a central role in cell survival, cellular proliferation, and tumor growth [29–31], which was negatively regulated by PTEN [36,37]. Previous studies identified that miR-106b inhibits PTEN expression through directly targetting its 3′-UTR in many cancer cells [23,26,27]. In the present study, our results also verified that PTEN is a target of miR-106b in ECC cells. In addition, overexpression of PTEN also inhibits proliferation and induces apoptosis in both Ishikawa and HEC-1A cells. It is well reported that miR-106b promotes the cell proliferation, invasion, and migration via regulating PTEN/PI3K/AKT signaling pathway in various cancers [23,26,27]. Then, we speculated that shikonin may exert suppressive effects on EEC cells via modulating PTEN/AKT/mTOR signaling pathway by suppressing miR-106b expression. As expected, shikonin treatment could inhibit the PTEN/AKT/mTOR signaling pathway in human EEC cells, but it was reactivated by miR-106b up-regulation. Collectively, these data indicated that shikonin blocks PTEN/AKT/mTOR signaling pathway via inhibiting miR-106b expression in human EEC cells (Figure 8).

In conclusion, our results demonstrated that shikonin inhibits cell growth in EEC cells via regulating the intracellular apoptotic signaling pathway. Additionally, we first demonstrated that miR-106b acts as an oncogene by targetting the tumor suppressor gene PTEN in EEC cells. More importantly, our results uncovered that shikonin possessed the suppressive effects on ECC cells via blocking miR-106b/PTEN/AKT/mTOR signaling pathway, suggesting shikonin could act as a promising anticancer agent for EEC treatment.

This work was supported by the Shanghai Municipal Health Bureau to further accelerate the development of Traditional Chinese Medicine Three Year Action Plan Project ‘Shanghai Zhu Gynecological School Heritage Research’ [grant number ZY3-CCCX-1-1013]; the Three Year Plan of Action for the Development of Traditional Chinese Medicine in Shanghai ‘Hu Guohua, Shanghai Old Doctor of Traditional Chinese Medicine Academic Experience Research Studio’ [grant number ZYSNXD-CC-MZY050]; the Shanghai Changning District Health and Family Planning Commission Special Training of Chinese Medicine: Young Doctor of Traditional Chinese Medicine Training Program [grant number 2015CNQNZY008]; and the Changning District Shanghai Science and Technology Fund Project [grant number CNKW2015Y14].

The authors declare that there are no competing interests associated with the manuscript.

C.H. and G.H. conceived and designed the experiments, performed the experiments, analyzed the data. G.H. contributed reagents/materials/analysis tools. C.H. wrote the paper. Both the authors read and agreed to the final version of manuscript.

CCK-8

cell counting kit-8

DMEM

Dulbecco’s Modified Eagle’s Medium

EEC

endometrioid endometrial cancer

mut

mutant

NC

negative control

PTEN

phosphatase and tensin homolog

wt

wild-type